L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH

The efficacy and safety of L-DEP (aspargase, liposomal doxorubicin, etoposide, and methylprednisolone) regimen combined with PD-1 Antibody an induction therapy for Epstein-Barr virus (EBV)-positive lymphoma-associated hemophagocytic lymphohistiocytosis.

Inclusion Criteria: * Diagnosed as lymphoma-Hemophagocytic Lymphohistiocytosis. * EBV-DNA in peripheral blood \> 1000 copies/ml or EBER detected in tissue specimens. * Age 18\~70，gender is not limited. * Estimated survival time ≥ 1 month. * Cardiac ultrasound LVEF≥50%; No Active bleeding of the internal organs(digestive tract, lung, brain, etc.); If the patient has dyspnea, oxygenation index \>250. * Signed informed consent. Exclusion Criteria: * Heart function above grade II (NYHA). * Severe myocardial injury：TNT、TNI、CK-MB \> 3 ULN. * Accumulated dose of doxorubicin above 400mg/m2 、epirubicin above 750mg/m2、pirarubicin above 800mg/m2 or the patients treated with anthracycline induced cardiovascular disease. * Pregnancy or lactating Women. * Allergic to pegylated liposomal doxorubicin，etoposide，or PD-1 antibody. * Thyroid dysfunction. * HIV antibody positivity. * Acute or chronic active hepatitis B (HBsAg positivity, HBV DNA negative acceptable), acute or chronic active hepatitis C (HCV antibody negatively acceptable; HCV antibody positivity, HCV RNA negative acceptable). * Participate in other clinical research at the same time. * The researchers considered that patients are not suitable for the study.